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Conclusions. Our data strongly suggest that the use of cate-Donor catecholamine use reduces acute allograft rejection and
cholamines in postmortal organ donors during intensive careimproves graft survival after cadaveric renal transplantation.
results in immunomodulating effects and improves graft sur-Background. Epidemiological data implicate that renal
vival in long-term follow-up. These findings may at least par-transplants from living unrelated donors result in superior sur-
tially be explained by down-regulating effects of adrenergicvival rates as compared with cadaveric grafts, despite a higher
substances on the expression of adhesion molecules (VCAM,degree of human lymphocyte antigen (HLA) mismatching. We
E-selectin) in the vessel walls of the graft.undertook a center-based case control study to identify donor-
specific determinants affecting early outcome in cadaveric
transplantation.
Methods. The study database consisted of 152 consecutive Kidney transplantation is well established worldwidecadaveric renal transplants performed at our center between
as a successful clinical procedure in the treatment ofJune 1989 and September 1998. Of these, 24 patients received
end-stage renal failure. The introduction of a new gener-a retransplant. Donor kidneys were allocated on the basis of
prospective HLA matching according to the Eurotransplant ation of immunosuppressants, the availability of more
rules of organ sharing. Immunosuppressive therapy consisted sophisticated preservation fluids, and improvements in
of a cyclosporine-based triple-drug regimen. In 67 recipients, recipient selection by human lymphocyte antigen (HLA)at least one acute rejection episode occurred during the first
matching have resulted in improved graft survival ratesmonth after transplantation. They were taken as cases, and
during the last decade that currently range from 80 tothe remaining 85 patients were the controls. Stepwise logistic
regression was done on donor-specific explanatory variables 90% after one year and 55 to 70% after five years follow-
obtained from standardized Eurotransplant Necrokidney re- ing transplantation, respectively [1–3]. Various factors
ports. In a secondary evaluation, the impact on graft survival affecting allograft survival in long-term follow-up havein long-term follow-up was further measured by applying a
been identified thus far [4–6], and it has been demon-Cox regression model. The mean follow-up of all transplant
strated previously that delayed graft function and therecipients was 3.8 years (sd 2.7 years).
Results. Donor age [odds ratio (OR) 1.05; 95% CI, 1.02 to occurrence of acute rejection episodes during the early
1.08], traumatic brain injury as cause of death (OR 2.75; 95% phase after transplantation are indicative for a poorer
CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95%
survival prognosis [7–10].CI, 1.47 to 6.12) were associated with an increased risk of acute
Epidemiological data from the United States suggestrejection, whereas donor use of dopamine (OR 0.22; 95% CI,
0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to that living-donor grafts from unrelated spouses do better
0.60) independently resulted in a significant beneficial effect. In in short- and long-term follow-up, as compared with
the multivariate Cox regression analysis, both donor treatment cadaveric transplants, despite an inferior degree of histo-
with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and noradrena-
compatibility between donor and recipient. It was sus-line (HR 0.30; 95% CI, 0.10 to 0.87) remained a significant
pected that approximately 10% of the cadaveric graftspredictor of superior graft survival in long-term follow-up.
are damaged before removal [11], but the underlying
mechanisms are poorly understood. Further insights into
1 See Editorial by Lu, p. 756. the etiology of this phenomenon may result in new strate-
gies for the prevention and treatment of allograft failure,Key words: kidney transplantation, acute rejection, brain death, cate-
cholamines, graft survival. as cadaver kidneys provide for the vast majority of all
transplants performed in Western countries. We did aReceived for publication December 8, 1998
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nors during intensive care was included for analysis, and cause of irreversible vascular rejection in three instances
and one technical failure (dissection of the renal artery),the impact on acute rejection and long-term graft sur-
vival was studied. respectively. These patients were excluded from analysis,
and nephrectomy was performed between two and six
days after transplantation.
METHODS
Information on each donor was obtained from stan-
The study base consisted of 152 consecutive cadaveric dardized Eurotransplant Necrokidney reports being rou-
renal transplants performed at the Renal Transplanta- tinely attached to the donor organ box after explantation.
tion Center of Mannheim between June 1989 and Sep- For statistical analysis, donor age, cold ischemia time,
tember 1998. One hundred and twenty-eight patients and serum creatinine were introduced as continuous
underwent a primary transplant, and 24 patients under- variables. Gender, cause of brain death (trauma/no
went a retransplant. The allocation of donor kidneys to trauma), occurrence of cardiac arrest and hypotensive
the individual recipient was centrally directed by Euro- period, and administration of vasopressors (dopamine/
transplant delivering a computerized, mainly HLA- noradrenaline/dobutamine/other adrenaline derivatives)
based, allocation algorithm. Most of the kidneys trans- were coded dichotomously. The kind of perfusate (UW-
planted came from foreign transplantation centers, and Belzer/Eurocollins/HTK) was included as an indicator
the proportion of transplants from local donors was variable.
44.1%. Donor-specific determinants that were identified to
Sixty-seven transplant recipients who experienced at affect early graft outcome were studied in long-term
least one acute rejection episode during the first month follow-up. Differences in the immunosuppressive regi-
after transplantation were taken as cases. The remaining men administered to the individual recipient (mycophe-
85 patients were the controls. An acute rejection episode nolate mofetil/induction therapy) and recipient-related
was proven by renal core biopsy (32 cases) or was diag- variables such as panel-reactive antibody levels and num-
nosed on the basis of clinical criteria only, which con- ber of previous transplants were included for multivari-
sisted of a significant rise of serum creatinine to a differ- ate analysis. Each transplant recipient was represented
ence of 0.4 mg/dl minimum within a 24-hour interval with in the database. No patient was lost to follow-up. Entry
a marked reduction of urine production in the absence of time was defined as the date of transplantation, and
drug toxicity or urinary tract obstruction and response follow-up was terminated on October 31, 1998, or at the
to steroid bolus therapy, as documented in a significant earlier date of graft failure and recipient death, respec-
decrease in serum creatinine within three days after ad- tively. The mean follow-up of all transplant recipients
ministration. Renal core biopsies were re-examined and was 3.8 years (sd 2.7 years). Ten individuals died with
graded per the Banff classification. a functioning allograft after a mean duration of 3.6 years
All patients received a cyclosporine-based triple-drug following transplantation (range 7 months to 7.3 years).
regimen. Cyclosporine was given orally on the first post- To focus on graft failure as a parameter of outcome,
operative day, and the initial dose (5 mg/kg b.i.d.) was censoring of patients who had died with a functioning
adjusted according to a target trough level between 180 kidney was performed.
and 250 ng/ml during the first three months after trans-
Statistical analysisplantation. Induction therapy with ATG or OKT3 was
administered in 32 instances in HLA-sensitized recipi- Group values are given as mean (sd) for numeric data
ents and in case of a retransplant. In 1996, azathioprine with normal distribution. Differences between groups
was replaced by mycophenolate mofetil. Antirejection were tested with the two-sample t-test for equal variances
therapy was initiated with high-dose methylpredniso- and those in the distribution of frequencies with the x2
lone. In case of steroid-resistant rejection, polyclonal test. Significance was defined according to a P value of
anti–T-lymphocyte globulins and/or OKT3 were applied. less than 0.05.
Demographics of cases and controls at time of trans- Logistic regression of the early-outcome parameters,
plantation are presented in Table 1. which were occurrences of acute rejection within 30 days
In a secondary analysis, the impact of donor-specific after transplantation, and a delayed graft function, as
determinants on the outcome parameter need for hemo- defined by the need for hemodialysis postoperation, re-
dialysis postoperation, which is indicative for delayed spectively, was done on the donor-specific explanatory
graft function was evaluated. Fifty-six transplant recipi- variables listed earlier in this article. The administration
ents requiring at least one session of hemodialysis after of mycophenolate mofetil and the application of anti–T-
transplantation before spontaneous recovery of graft cell immunoglobulins for induction therapy were in-
function occurred were taken as cases, and 92 patients cluded in the regression analysis to adjust for different
with immediate graft function were the controls. In four treatment modalities during the study period. Stepwise
backward estimation was performed by removal of vari-patients, the transplanted kidney never functioned be-
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Table 1. Characteristics of cases and controls at date of transplantation
Cases Controls
(Acute rejection) (No acute rejection)
Recipient characteristics N567 N585 P value
Age years 46.4612.4 47.3 611.4 0.64
Gender male 38 (56.7%) 54 (63.5%) 0.39
Time on waiting list years 2.7662.36 2.73 62.53 0.93
Original disease 0.13
DM 4 (6.0%) 5 (5.9%)
GN 31 (46.3%) 39 (45.9%)
IN 9 (13.4%) 4 (4.7%)
PC 11 (16.4%) 8 (9.4%)
Other 6 (9.0%) 14 (16.4%)
Unknown 6 (8.9%) 15 (17.7%)
Previous transplant 0.99
N50 56 (83.6%) 72 (84.7%)
N51 9 (13.4%) 11 (12.9%)
N52 1 (1.5%) 1 (1.2%)
N53 1 (1.5%) 1 (1.2%)
HLA mismatchesa 0.51
N50 9 (13.4%) 16 (19.0%)
N51 11 (16.4%) 9 (10.7%)
N52 14 (20.9%) 24 (28.6%)
N53 24 (35.8%) 26 (31.0%)
N54 7 (10.5%) 9 (10.7%)
N55 1 (1.5%) 0
N56 1 (1.5%) 0
Immunosuppression (MMF) 15 (22.4%) 27 (31.8%) 0.20
Induction (ATG or OKT3) 16 (23.9%) 16 (18.8%) 0.45
Panel reactivity (.5%) 6 (9.0%) 6 (7.1%) 0.67
Abbreviations are: DM, diabetes mellitus; GN, glomerulonephritis; IN, interstitial nephritis; PC, polycystic kidneys; MMF, mycophenolate mofetil.
a Donor HLA typing not available in one control
ables from the full model at a significance level equal to sions (46.7%) and traumatic brain injuries (43.4%) ac-
or higher than 0.05. Maximum likelihood estimates are counted for the most frequent causes of death. Trans-
expressed as odds ratios (OR), with 95% confidence plants from male donors were predominant to a pro-
intervals being displayed for a one-unit change in the portion of almost two thirds. Because donor organs were
variable. allocated on the basis of HLA matching, the import rate
Cox’s regression model was applied for statistical anal- of organs being retrieved by co-operating foreign centers
ysis of the multiple record data in long-term follow- from the Eurotransplant region was high (55.9%), and
up. The analysis was done with uncensored failure data a minority of all donors only (11.9%) shared less than
because of complete follow-up of all recipients. Death three HLA antigens with the recipient. Cold ischemia
as cause of graft failure was censored in a secondary time ranged between 13 and 54 hours, with a mean of
analysis. All results are presented as hazard ratios, with 23.8 hours. A percentage of all donors (80.3%) received
a 95% confidence interval for a one-unit change in the vasopressors during intensive care prior to the diagnosis
variable. of brain death that were administered one by one or
Cumulative frequencies during the first month after combined with one another in several instances, and
transplantation were plotted and summarized the condi- there was no difference in blood pressure (121 6
tional probability of events during each time band (in 20/70 6 12 mm Hg vs. 118 6 17/73 6 12 mm Hg, P 5
days) from the date of transplantation (day 0). Graft 0.52) and in the 24-hour urine output (6519 6 4539 ml
survival estimates were generated according to the vs. 6172 6 4138 ml, P 5 0.72) between the catecholamine
Kaplan–Meier method. The log-rank test was used to treated and untreated donors.
test the equality of the failure/survivor function across The application of logistic regression to the case-con-
different groups. Statistical analysis of the data was per- trol design of this study revealed various donor-specific
formed with Stata Statistical Software for MS windows
determinants that were associated with an increased risk(release 5.0).
of acute rejection episode during the first month after
transplantation. Mismatches on HLA-DR between do-
RESULTS nor and recipient, traumatic cause of death, and donor
age predicted a higher probability of acute rejection epi-The mean age of all donors was 39.9 years, ranging
between 5.3 and 71.1 years. Primary cerebrovascular le- sode, whereas both donor treatment with dopamine and
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Table 2. Multivariante logistic regression of the main outcome
parameter acute rejection on donor-specific
explanatory variables
95% Confidence
Variable Odds ratio interval P value
Age years 1.06 1.03–1.10 ,0.001
Gender male 1.28 0.54–3.07 0.58
Serum creatinine mg/dl 2.83 0.53–15.03 0.22
Head trauma 3.57 1.30–9.79 0.013
Cardiac arrest 2.05 0.44–9.64 0.36
Hypotensive period 0.67 0.28–1.58 0.36
Catecholamines
Noradrenaline 0.21 0.07–0.67 0.008
Dopamine 0.22 0.08–0.58 0.002
Dobutamine 1.61 0.43–6.02 0.48
Other vasopressors 1.74 0.41–7.35 0.45
Fig. 1. Cumulative incidence of the first acute rejection episode duringPerfusion solution
the first month after transplantation relative to donor treatment withUW-Belzer 1.80 0.46–7.04 0.40
dopamine (log rank, P , 0.001; dopamine 1, N 5 110; dopamine 2,Eurocollins 1.34 0.21–8.37 0.76
N 5 42).Cold ischemia hours 0.96 0.90–1.03 0.24
HLA-mismatches
HLA-A 0.95 0.52–1.74 0.87
HLA-B 1.22 0.58–2.60 0.60
HLA-DR 3.28 1.38–7.80 0.007 Table 4. Recipient characteristics relative to donor treatment
Immunosuppression with dopamine
Mycophenolate mofetil 0.31 0.10–0.91 0.033
Dopamine No dopamineInduction (ATG/OKT3) 0.75 0.28–2.05 0.58
Recipient characteristics N5110 N542 P value
Age years 46.2611.7 48.8612.1 0.23
Gender male 66 (60.0%) 26 (61.9%) 0.83
Previous transplant 17 (15.5%) 7 (16.7%) 0.86Table 3. Multivariate logistic regression of the main
HLA-mismatchingoutcome parameter delayed graft function on
HLA-A 0.8360.70 0.8360.73 0.99donor-specific explanatory variables
HLA-B 0.7460.60 0.6760.65 0.49
95% Confidence P HLA-DR 0.5760.52 0.5760.59 0.98
Variable Odds ratio interval value Cytotoxic panel reactivity
($5%) 7 (6.4%) 5 (11.9%) 0.26Age years 1.03 1.00–1.07 0.044 Previous blood transfusion 73 (66.4%) 31 (73.8%) 0.38Gender male 2.23 0.90–5.51 0.082 ImmunosuppressionSerum creatinine mg/dl 1.33 0.31–5.71 0.71 Mycophenolate mofetil 30 (27.3%) 12 (28.6%) 0.87Head trauma 1.09 0.41–2.93 0.87 Induction (ATG/OKT3) 22 (20.0%) 10 (23.8%) 0.61Cardiac arrest 0.28 0.06–1.30 0.11 Acute rejection episodeHypotensive period 0.88 0.37–2.09 0.78 All 40 (36.4%) 27 (64.3%) 0.002Catecholamines Biopsy proven 17 (15.5%) 15 (35.7%) 0.006Noradrenaline 4.82 1.71–13.64 0.003 Banff grade IIb/III 12 (10.9%) 8 (19.1%) 0.18Dopamine 0.49 0.20–1.18 0.11
Dobutamine 2.25 0.58–8.67 0.24
Other vasopressors 2.01 0.55–7.33 0.29
Perfusion solution
UW-Belzer 1.49 0.39–5.78 0.56
3), and cold ischemia time became a significant variableEurocollins 3.24 0.53–19.67 0.20
Cold ischemia hours 1.06 0.99–1.13 0.077 as well when nonsignificant terms were removed from
HLA-mismatches the full model by backward stepwise estimation (OR
HLA-A 1.24 0.68–2.25 0.49
1.07; 95% CI, 1.02 to 1.13).HLA-B 0.84 0.39–1.80 0.65
HLA-DR 1.62 0.71–3.72 0.25 In Figure 1, cumulative frequencies of first acute rejec-
Immunosuppression tion episode during the first month after transplantation
Mycophenolate mofetil 0.82 0.28–2.38 0.72
are plotted relative to donor treatment with dopamine.Induction (ATG/OKT3) 1.00 0.37–2.74 0.99
Looking at the data in detail, the recipient groups did
not differ in terms of HLA mismatching, cytotoxic panel
reactivity, or immunosuppressive medication (Table 4),
and dopamine-treated and nontreated grafts werenoradrenaline provided for a significant beneficial effect
(Table 2). These results could be confirmed when the equally distributed over the entire study period. How-
ever, the administration of dopamine to the donor duringanalysis was restricted to primary transplants only, but
not in retransplants, probably because of the limited intensive care had a significant effect on the incidence
of acute allograft rejection that could be confirmed ifnumber of cases. Doing the analysis on the outcome
parameter need for hemodialysis postoperation nor- the evaluation was restricted to biopsy-proven rejection
episodes only (OR 0.27; 95% CI, 0.11 to 0.66). Of these,adrenaline was a determinant of an increased risk (Table
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Fig. 2. Cumulative incidence of the first acute rejection episode during the first month after transplantation relative to the donor treatment with
dopamine. (A) Trauma (log rank, P , 0.001; dopamine 1, N 5 18; dopamine 2, N 5 48). (B) No trauma (log rank, P 5 0.162; dopamine 1,
N 5 24; dopamine 2, N 5 62).
20 cases (62.5%) revealed endothelialitis (Banff grade
IIb/III) on microscopic examination.
Multivariate logistic regression analysis indicated that
transplant patients receiving a kidney from a donor who
had died from trauma were at higher risk of early allo-
graft rejection, which could not be demonstrated in the
univariate analysis. Dividing the data into groups by
cause of death (trauma yes/no), it became quite clear
that the statistical association between a lower incidence
of graft rejection and donor dopamine treatment was
stronger if the donor had died from head trauma (Fig. 2).
Forty-two donors were treated with noradrenaline.
Of these, 29 (69.1%) were treated in combination with
dopamine. On the other hand, 81 donors (73.6%) out Fig. 3. Cumulative incidence of the first acute rejection episode during
of a total of 110 who did not receive noradrenaline were the first month after transplantation relative to the donor treatment
with noradrenaline. Noradrenaline 1, N 5 42; noradrenaline 2, N 5treated with dopamine. Pearson’s x2 test excluded un-
110; log rank, P 5 0.017.equal distribution (P 5 0.57), indicating that noradrena-
line use additionally contributed to a lower cumulative
incidence of early acute rejection (Fig. 3), irrespective
of dopamine treatment and despite a significant associa- able, and some recipient-related risk factors such as cyto-
tion to an increased risk of delayed graft function. Recipi- toxic panel reactivity and previous transplants were
ent characteristics relative to donor treatment with nor- considered for multivariate analysis as well. Donor age
adrenaline are presented in Table 5, showing some and mismatch on HLA-DR resulted in increased hazards
disparity in the immunosuppressive medication between during long-term follow-up, whereas cold ischemia being
the different groups. Nevertheless, when eliminating my- significantly associated with delayed graft function did
cophenolate mofetil-treated patients from the analysis not affect graft survival (Table 6).
donor noradrenaline use still resulted in significantly less
acute rejection (25.0 vs. 52.2%, P 5 0.027).
DISCUSSIONThe donor use of catecholamines remained to be a
significant determinant of improved graft survival, even Previous data on the efficacy of dopamine infusion in
the field of renal transplantation are conflicting [12–14],during long-term follow-up in the univariate analysis
(Figs. 4 and 5), which was confirmed by multivariate and the majority of the studies failed to demonstrate any
significant effect when dopamine was administered toCox regression analysis. To control for changes in the
immunosuppressive regimen over time, different thera- the recipients following transplantation [15–18]. Several
reports on an adverse association between immediatepeutic modalities were included as an explanatory vari-
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Recipient characteristics N542 N5110 P value
Age years 48.1612.0 46.4611.8 0.45
Gender male 26 (61.9%) 66 (60.0%) 0.83
Previous transplant 4 (9.5%) 16 (14.6%) 0.50
HLA-mismatches
HLA-A 1.0760.72 0.7560.68 0.011
HLA-B 1.0260.65 0.6160.56 ,0.001
HLA-DR 0.6360.58 0.5560.52 0.37
Cytotoxic panel reactivity
(.5%) 3 (7.1%) 9 (8.2%) 0.83
Previous blood transfusion 29 (69.1%) 75 (68.2%) 0.92
Immunosuppression
Mycophenolate mofetil 22 (52.4%) 20 (18.2%) ,0.001
Fig. 5. Kaplan-Meier estimates of graft survival relative to donor treat-Induction (ATG/OKT3) 3 (7.1%) 29 (26.4%) 0.009
ment during long-term follow-up. Ten patients who died with a function-Acute rejection episode
ing graft were censored from analysis at the date of death (log rank,All 12 (28.6%) 55 (50.0%) 0.017
P 5 0.039).Biopsy proven 4 (9.5%) 28 (25.5%) 0.031
Banff grade IIb/III 2 (4.8%) 18 (16.4%) 0.058
Table 6. Cox regression of donor-specific explanatory variables on
graft survival in long-term follow-up
Hazard 95% Confidence
Variable ratio interval Pvalue
Dopamine 0.44 0.22–0.84 0.014
Noradrenaline 0.30 0.10–0.87 0.027
Donor age 1.03 1.01–1.05 0.009
Cause of brain death
Head trauma 1.25 0.63–2.49 0.52
Cold ischemia time 0.98 0.93–1.02 0.31
HLA-mismatches
HLA-A 1.14 0.70–1.85 0.61
HLA-B 0.82 0.43–1.57 0.54
HLA-DR 2.00 1.05–3.81 0.036
Previous transplant 2.75 0.96–7.84 0.059
Cytotoxic panel reactivity
(.5%) 2.92 1.23–6.91 0.015
Immunosuppression
Mycophenolate mofetil 1.31 0.50–3.44 0.58Fig. 4. Kaplan-Meier estimates of graft survival relative to donor treat-
Induction (ATG/OKT3) 0.72 0.27–1.95 0.52ment with catacholamines during long-term follow-up. Patients who
died with a functioning graft were not censored (log rank, P 5 0.017). Differences in recipient characteristics (previous transplants/cytotoxic panel
reactivity) and treatment modalities (induction therapy with anti-T-cell antibod-
ies/administration of mycophenolate mofetil) are included for multivariate analy-
sis. Patients who died with a functioning graft are not censored from this analysis.
graft function and the administration of inotropic sup-
port or vasopressors to the donor have been published
thus far [18–20]. On the other hand, no dopamine use dead dogs [24]. Nevertheless, data on catecholamines
demonstrating an immunomodulating effect in clinicalto the donor was identified as a determinant of initial
nonfunction in a Canadian study applying a multivariate transplantation have not been reported previously.
Although in our study no cytokines or adhesion mole-analysis on 16 putative risk factors [21]. In liver trans-
plantation, the use of high-dose catecholamine in brain- cules were measured, we now summarize some data from
the literature that might help to understand our findings.dead patients was associated with a poor outcome after
transplantation [22]. Furthermore, dopamine adminis- Accumulating evidence from the last few years reveals
that cells from the central nervous system are capabletration has been suggested to be a contributing factor to
the reduction of hepatic mitochondrial redox state in of producing an inflammatory response to a variety of
insults, including trauma and ischemia [25]. In particular,hypotensive brain-dead patients [23], which is, however,
in contrast to an experimental study showing that the it has been demonstrated that the expression of mRNA
coding for tumor necrosis factor-a (TNF-a), inter-combined administration of vasopressin and epinephrine
has a synergistic effect in improving the hemodynamics leukin-1 (IL-1), and interleukin-6 (IL-6) is up-regulated
in experimental brain ischemia [26–28]. TNF-a is presentand maintenance of the energy status of the liver in brain-
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in neuroneal cells around the infarcted tissue [26], and fect on early acute rejection (Fig. 3). Because donor
noradrenaline use was clearly associated with a higherIL-1b protein is synthesized early in cerebral ischemia
[27, 28]. Both TNF-a and IL-1b cause the expression incidence of dialysis after transplantation, it remains to
be seen whether noradrenaline plays a causal role or isof adhesion molecules on the surface of endothelial cells,
which play a key role in leukocyte–endothelial interac- just indicative for an increased susceptibility to acute
tubular necrosis in a donor category, which was probablytions [29–31]. It also has been demonstrated that E-
selectin (CD62E), intercellular adhesion molecule-1 hemodynamically unstable. Registry data indicate that
acute rejection occurs less frequently in grafts with imme-(ICAM-1; CD54), and vascular cellular adhesion mole-
cule-1 (VCAM-1) are up-regulated in experimental in diate function, and delayed graft function has been iden-
tified to be predictive for graft failure during short- andvivo and in vitro models of traumatic brain injury and
cerebral ischemia [32, 33]. Recently, a striking difference long-term follow-up even in the absence of acute rejec-
tion [36, 37]. Whether delayed graft function leads toin the level of adhesion molecule expression between
cadaver and living related-donor kidneys has been re- an injury response-lowering graft survival by antigen-
dependent or antigen-independent mechanisms is still aported. High levels of endothelial E-selectin and proxi-
mal tubular expression of ICAM-1, VCAM-1, and HLA matter of debate in the literature [38, 39] and our data
do not confirm an adverse association between delayedclass II were detected by immunohistochemical staining
in biopsies from cadaver donor kidneys, whereas no ex- graft function and rejection at a statistically significant
level (x2 5 3.24, P 5 0.072). A clinical phase I trialpression of these markers was observed in the living
related donor kidneys (abstract 371; Koo et al; XVII of immunosuppression with anti–ICAM-1 monoclonal
antibodies in renal allograft recipients resulted in sig-World Congress of the Transplantation Society, Montreal
1998). Thus, it is very likely that cytokines originating nificantly less delayed graft function and less rejection
[40]. On the other hand, a blockade of ICAM-1 using afrom the central nervous system enter the circulation
after an ischemic or traumatic lesion stimulates the ex- monoclonal antibody directed against the alpha chain of
leukocyte function-associated antigen-1 (LFA-1) had nopression of various vascular adhesion molecules in the
periphery. This might be more pronounced if the integ- effect on the incidence of acute rejection in a randomized
clinical trial. The comparison was made with rabbit anti-rity of the central nervous system is damaged severely,
possibly explaining our observation that donor treatment thymocyte globulin as induction treatment in first kidney
transplantation [41], which is, however, not necessarilywas more effective in patients receiving a transplant
from a donor who had died from traumatic brain injury in contrast to the findings of this study because the molec-
ular mechanisms that are mediated by the infusion of(Fig. 2).
Leukocyte invasion of the graft is a prerequisite for adrenergic substances during brain death are not well
understood in total.acute rejection because antigen presentation is known
to be the key initiating interaction promoting the subse- It should be emphasized that donor use of dopamine
and noradrenaline was simply coded as a binary variablequent T-cell–mediated allo-immune response. Leuko-
cyte migration into the tissues requires the expression in this study because more detailed information on
duration and dosage was not available from the Euro-of adhesion molecules on the surface of activated endo-
thelium, which are controlled by various inflammatory transplant Necrokidney reports. Nevertheless, our data
strongly suggest that the infusion of adrenergic agentsmediators such as TNF-a and IL-1b [29, 30]. More de-
tailed studies revealed that elevated intracellular con- to brain-dead organ donors during intensive care before
removal of the kidneys affects the incidence of earlycentrations of cyclic adenosine 39,59-monophosphatase
(cAMP) induced by pharmacological stimulation of ad- acute rejection after transplantation. This finding could
even be confirmed when the analysis was restricted toenolate cyclase or inhibition of phosphodiesterase lowers
the synthesis and expression of TNF-induced endothelial biopsy-proven rejections only. We did not perform pro-
tocol biopsies in our series, but it has been our policyadhesion molecules in culture [34]. Additionally, it was
recently demonstrated that pretreatment with inotropes thus far to always do a biopsy in cases of steroid-resistant
rejection and persistent nonfunction. Thus, the propor-(amrinone and dopamine) at clinically relevant concen-
trations inhibits IL-1b–induced expression of adhesion tion of severe acute rejection episodes was high in these
patients, and almost two thirds revealed endotheliitismolecules in endothelial cell monolayers from human
umbilical veins. Dopamine mainly affected the down- (Banff grade IIb/III) on microscopic examination (Ta-
bles 4 and 5). It is noteworthy that the beneficial effectregulation of E-selectin by a mean of 50% at a concen-
tration of 2 mg/ml. In higher concentrations (20 mg/ml), on acute rejection was independent from alterations in
the immunosuppressive treatment of the recipients dur-comparable to a clinically relevant a-adrenergic dose,
dopamine was able to reverse the expression of ICAM-1 ing the entire study period.
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